In conclusion, in the present study, we have demonstrated that (1) more than half of patients with prostate cancer undergoing ADT progressed in the severity of their frailty syndrome; (2) cross-sectional studies performed in the same patients at baseline and 1 year later show that some inflammatory cells and soluble inflammatory markers in blood are associated with the severity of the frailty syndrome; and (3) a high Il-6 level and low lymphocyte count distinguishes patients whose frailty syndrome will progress over time. The gene discussed is IL6; the disease is prostate cancer.